Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector

Meizhen Feng, William H. Jackson, Corey K. Goldman, Claudine Rancourt, Minghui Wang, Sandra K. Dusing, Gene Siegal, David T. Curiel

Research output: Contribution to journalArticle

121 Scopus citations

Abstract

Gene therapy to correct defective genes requires efficient gene delivery and long-term gene expression. The available vector systems have not allowed the simultaneous achievement of both goals. We have developed a chimeric viral vector system that incorporates favorable aspects of both adenoviral and retroviral vectors. Adenoviral vectors induce target cells to function as transient retroviral producer cells in vivo. The progeny retroviral vector particles are then able to stably transduce neighboring cells. In this system, the nonintegrative adenoviral vector is rendered functionally integrative via the intermediate generation of a retroviral producer cell. The chimeric vectors may allow realization of the requisite goals for specific gene-therapy applications.

Original languageEnglish
Pages (from-to)866-870
Number of pages5
JournalNature Biotechnology
Volume15
Issue number9
DOIs
StatePublished - Sep 1997
Externally publishedYes

Keywords

  • Chimeric viral vectors
  • Gene therapy

Fingerprint Dive into the research topics of 'Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector'. Together they form a unique fingerprint.

  • Cite this

    Feng, M., Jackson, W. H., Goldman, C. K., Rancourt, C., Wang, M., Dusing, S. K., Siegal, G., & Curiel, D. T. (1997). Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nature Biotechnology, 15(9), 866-870. https://doi.org/10.1038/nbt0997-866